AAP
BLTE

Arax Advisory Partners’s Belite Bio BLTE Stock Holding History

Arax Advisory Partners’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308 Buy
+2
New +$307 ﹤0.01% 5058

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arax Advisory Partners's BLTE Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Belite Bio (BLTE) in Q2 2026: 2 shares worth $308. The stake represents ﹤0.01% of the portfolio and ranks #5058 among its holdings.

81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Arax Advisory Partners held 2 shares of Belite Bio worth $308 as of Q2 2026.
  • Belite Bio was a new Arax Advisory Partners position in Q2 2026.
  • Belite Bio made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5058 holding.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.